MonoMac-1 Cell Line CD16 Expression Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable cell line model for studying CD16 expression and evaluating drug candidates, as primary tissue culture models are inconsistent and difficult to work with due to donor variation.
Innovation Solution
A method involving the MonoMac-1 cell line is used, where monocytes are cultured with phorbol-12-myristate-13-acetate (PMA), lipopolysaccharide (LPS), macrophage colony-stimulating factor (MCSF), dexamethasone (DEX), TNFα, and IFNγ to induce expression of CD16, CD163, and CD4, allowing for the screening of compounds that modulate these proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary tissue culture models are used to study CD16 expression, then the model reflects in vivo conditions, but the consistency and reliability deteriorate due to donor variation
Solution Approach 1:
The patent uses MonoMac-1 cell line as a copy/analogue of primary monocytes, which allows studying CD16 expression and drug candidate evaluation without the variability inherent in primary cells from different donors. The cell line replicates the essential functional characteristics while providing consistency.
Solution Approach 2:
The patent induces CD16 expression in MonoMac-1 cells by changing cultural parameters - specifically adding PMA, LPS, and other cytokines to the culture medium. This transforms the cell line from a non-CD16 expressing state to a CD16 expressing state that mimics activated primary monocytes.
2Quantity of substance
If multiple cytokines and activators are used to induce CD16 expression, then the expression level increases, but the complexity of the culture system increases
Solution Approach 1:
The patent applies PMA and LPS in a preliminary step before adding cytokines like MCSF and dexamethasone. This sequential approach builds up CD16 expression progressively, allowing each agent to work optimally without overwhelming the cells with all stimulants simultaneously.
Solution Approach 2:
The culture protocol is divided into distinct phases: initial activation with PMA/LPS, followed by cytokine treatment with MCSF and dexamethasone, and optionally further maturation with TNFα and IFNγ. This segmentation allows control over the induction process and optimization of each step.
Data Source
AI summary
The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.